ReviewLife (Basel, Switzerland)2021
Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Dietary Omega-3 PUFAs in Metabolic Disease Research: A Decade of Omics-Enabled Insights (2014-2024).Nutrients · 2025Pooled it
- Effects of 28-day simvastatin administration on emotional processing, reward learning, working memory, and salivary cortisol in healthy participants at-risk for depression: OxSTEP, an online experimental medicine trial.Psychological medicine · 2025Trial
- Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Association between NHHR and depression symptoms among U.S. adults with hypertension: a cross sectional.BMC cardiovascular disorders · 2026Article
- Glucose levels are associated with mood, but the association is mediated by ratings of metabolic state.EBioMedicine · 2026Observational
- The adiponectin-depression nexus: a brief review of mechanisms and therapeutic opportunities.Metabolic brain disease · 2026Review
- Sodium-Glucose Cotransporter-2 Inhibitors in Mood Disorders: A Narrative Review of Mechanisms, Evidence, and Challenges.Neuropsychiatric disease and treatment · 2026Review
- Associations of uric acid and lipids with depression, dimensions of depression and anxiety symptoms.Discover mental health · 2025Article
- GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective.Life (Basel, Switzerland) · 2025Review
- The Role of Metabolic Disorders and Laboratory Abnormalities in Wound Healing and Recovery in Geriatric and Non-Geriatric Orthopedic Patients in Poland-Prospective Research.Journal of clinical medicine · 2025Article
- Monitoring of mental health in occupational populations: a study on the role and application of HDL-related inflammatory index.Frontiers in public health · 2025Article
- Sex differences of the lipid profile, impulsivity and suicidality in psychiatric inpatients.Frontiers in psychiatry · 2025Article
- Understanding immune system dysfunction and its context in mood disorders: psychoneuroimmunoendocrinology and clinical interventions.Military Medical Research · 2024Review
- Better understanding of c-reactive protein and leukocytes in psychiatric inpatients with affective disorders: A biopsychosocial approach.World journal of clinical cases · 2024Article
- Are the antidepressant effects of insulin-sensitizing medications related to improvements in metabolic markers?Translational psychiatry · 2022Review
- Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression.Brain sciences · 2022Review
- Metformin for the Improvement of Comorbid Depression Symptoms in Diabetic Patients: A Systematic Review.Cureus · 2022Review
- Possible Association of Cholesterol as a Biomarker in Suicide Behavior.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) and bipolar disorder (BD) are often chronic with many patients not responding to available treatments. As these mood disorders are frequently associated with metabolic dysfunction, there has been increased interest in novel treatments that would target metabolic pathways. The objectives of this scoping review were to synthesize evidence on the impact on mood symptoms of lipid lowering agents and anti-diabetics drugs, while also reviewing current knowledge on the association between mood disorders and dyslipidemia or hyperglycemia. We propose that metabolic dysfunction is prevalent in both MDD and BD and it may contribute to the development of these disorders through a variety of pathophysiological processes including inflammation, brain structural changes, hormonal alterations, neurotransmitter disruptions, alteration on brain cholesterol, central insulin resistance, and changes in gut microbiota. Current evidence is conflicting on the use of statins, polyunsaturated fatty acids, thiazolidinediones, glucagon-like peptide agonists, metformin, or insulin for the treatment of MDD and BD. Given the paucity of high-quality randomized controlled trials, additional studies are needed before any of these medications can be repurposed in routine clinical practice. Future trials need to enrich patient recruitment, include evaluations of mechanism of action, and explore differential effects on specific symptom domains such as anhedonia, suicidality, and cognition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.